Exact Sciences Corporation (EXAS)
NASDAQ: EXAS · Real-Time Price · USD
103.43
+0.14 (0.14%)
Feb 20, 2026, 4:00 PM EST - Market closed
Exact Sciences Revenue
In the year 2025, Exact Sciences had annual revenue of $3.25B with 17.69% growth.
Revenue (ttm)
$2.37B
Revenue Growth
+15.80%
P/S Ratio
6.08
Revenue / Employee
$450,971
Employees
7,200
Market Cap
19.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.25B | 488.12M | 17.69% |
| Dec 31, 2024 | 2.76B | 259.10M | 10.37% |
| Dec 31, 2023 | 2.50B | 415.49M | 19.93% |
| Dec 31, 2022 | 2.08B | 317.19M | 17.95% |
| Dec 31, 2021 | 1.77B | 275.70M | 18.49% |
| Dec 31, 2020 | 1.49B | 615.10M | 70.19% |
| Dec 31, 2019 | 876.29M | 421.83M | 92.82% |
| Dec 31, 2018 | 454.46M | 188.47M | 70.86% |
| Dec 31, 2017 | 265.99M | 166.61M | 167.66% |
| Dec 31, 2016 | 99.38M | 59.94M | 151.99% |
| Dec 31, 2015 | 39.44M | 37.64M | 2,093.38% |
| Dec 31, 2014 | 1.80M | -2.35M | -56.61% |
| Dec 31, 2013 | 4.14M | - | - |
| Dec 31, 2012 | 4.14M | -19.00K | -0.46% |
| Dec 31, 2011 | 4.16M | -1.18M | -22.10% |
| Dec 31, 2010 | 5.34M | 586.00K | 12.32% |
| Dec 31, 2009 | 4.76M | 5.63M | - |
| Dec 31, 2008 | -867.00K | -2.67M | - |
| Dec 31, 2007 | 1.80M | -2.95M | -62.15% |
| Dec 31, 2006 | 4.75M | 500.00K | 11.76% |
| Dec 31, 2005 | 4.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IQVIA Holdings | 16.31B |
| Labcorp Holdings | 13.95B |
| Quest Diagnostics | 11.04B |
| Agilent Technologies | 6.95B |
| Illumina | 4.34B |
| Mettler-Toledo International | 4.03B |
| Waters | 3.17B |
| Revvity | 2.86B |
EXAS News
- 1 day ago - Exact Sciences Stockholders Approve Acquisition by Abbott - Business Wire
- 6 days ago - Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells - Seeking Alpha
- 8 days ago - Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results - Business Wire
- 9 days ago - Alger Mid Cap 40 ETF Q4 2025 Portfolio Update - Seeking Alpha
- 9 days ago - Baron Opportunity Fund Q4 2025 Portfolio Activity - Seeking Alpha
- 15 days ago - Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences' '746 Patent - Business Wire
- 18 days ago - Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests - Business Wire
- 18 days ago - Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide - Business Wire